TY - JOUR T1 - Back to school: use of Dried Blood Spot for the detection of SARS-CoV-2-specific immunoglobulin G (IgG) among schoolchildren in Milan, Italy JF - medRxiv DO - 10.1101/2020.07.29.20164186 SP - 2020.07.29.20164186 AU - Antonella Amendola AU - Silvia Bianchi AU - Maria Gori AU - Lucia Barcellini AU - Daniela Colzani AU - Marta Canuti AU - Vania Giacomet AU - Valentina Fabiano AU - Laura Folgori AU - Gian Vincenzo Zuccotti AU - Elisabetta Tanzi Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/30/2020.07.29.20164186.abstract N2 - Serological surveillance is necessary to the reestablishment of school activities in safe conditions and to avoid school-related outbreaks. In this study, DBS (Dried Blood Spots) have proven to be a simple, rapid and reliable sample collection tool for detecting antibodies against SARS-CoV-2 by ELISA test compared to matched serum samples from venous sampling (R2=0.9553; Pearson’s coefficient=0.98; Cohen’s unweighted k=0.93; overall agreement=96.2%). This approach may facilitate sample collection from schoolchildren for serological surveys useful to an adequate risk-assessment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from the Ethics Committee of the Buzzi Hospital: Prot. N 0018927All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the manuscript. ER -